The short version of reference standard fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-02 and is reviewed periodically as new material appears.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Macimorelin (INN) – or Macrilen (trade name) – is a drug that was developed by Aeterna Zentaris for use in the diagnosis of adult growth hormone deficiency. Macimorelin acetate, the salt formulation, is a synthetic growth hormone secretagogue receptor agonist. It is a growth hormone secretagogue receptor (ghrelin receptor) agonist, causing release of growth hormone from the pituitary gland. Macimorelin acetate is described chemically as D-Tryptophanamide, 2-methylalanyl-N-[(1R)-1-(formylamino)-2-(1H-indol-3-yl)ethyl]-acetate. Macimorelin (Macrilen) was invented and first synthesized at University of Montpellier, Centre National de la Recherche Scientitifique (CNRS), France. This transpired from a long-lasting research collaboration with Aeterna Zentaris. Aeterna Zentaris later in-licensed macimorelin as a development candidate from the CNRS and proceeded with the pre-clinical and clinical development of the compound. As of January 2014, it was in Phase III clinical trials. The phase III trial for growth hormone deficiency is expected to be complete in December 2016. As of December 2017, it was FDA-approved as a method to diagnose growth hormone deficiency. Traditionally, growth hormone deficiency was diagnosed via means of insulin tolerance test (IST) or glucagon stimulation test (GST). These two means are done parenterally, whereas Macrilen boasts an oral formulation for ease of administration for patients and providers. In November 2018 Novo Nordisk would acquire the rights to Macrilen, at a cost of $145 million.
Hox genes A subset of highly conserved homeobox-containing genes whose protein products function as transcription factors essential for the proper organization of the body plan in developing animal embryos, ensuring that the correct structures are formed in the correct places. Hox genes are usually arranged on a chromosome in tandem arrays and are expressed sequentially during development, with the sequence of gene activation corresponding to their physical arrangement within the genome and/or the physical layout of the tissues in which they are expressed along the organism's anterior–posterior axis.
== Regulatory harmonization == In an effort to reduce the burden on manufacturers applying for orphan drug status, the FDA and the European Medicines Agency (EMA) agreed in late 2007 to utilize a common application process for both agencies. However, the two agencies will continue to maintain separate approval processes.
=== Australia === The following programs of study have currently been approved by the Dental Board of Australia for the profession of dental prosthetics. On successful completion of the selected courses, individuals are required to register with the Australian Health Practitioner Regulation Agency to practice legally as a dental prosthetist.
Oripavine is an opioid and the major metabolite of thebaine. It is the precursor to the semi-synthetic compounds etorphine and buprenorphine. Although this chemical compound has analgesic potency comparable to morphine, it is not used clinically due to severe adverse effects and a low therapeutic index. Being a precursor to a series of extremely strong opioids, oripavine is a controlled substance in some jurisdictions.
Sources: en.wikipedia.org
In Food and Allied Workers Union and Another v The Cold Chain, an important case in South African labour law, the Labour Court held that there was nothing absurd in permitting a senior managerial employee to participate in the activities of a trade union, provided that the employee complies with his contractual obligations. In this case, the employee was offered a managerial position as an alternative to retrenchment, on condition that he no longer participated in the activities of the trade union. When he refused, he was retrenched. The court did not hesitate to find the dismissal to be automatically unfair.
=== Plasma fractionation and Wiener directorship === In 1952, operation commenced plasma fractionation. Thereafter the range of antivenoms increased, including those against other snake species such as death adder (Acanthophis antarcticus) and the taipan (Oxyuranus scutellatus), plus spiders including the redback (Latrodectus hasselti) and – after much difficulty – the Sydney funnel-web (Atrax robustus). Much of this work, including the introduction in 1962 of a polyvalent antivenom against all of the major terrestrial Australian snakes, occurred under the direction of Saul Wiener, while from 1966 until the mid-1990s, venom research was coordinated by the eccentric but dedicated Struan Sutherland, who in 1979 released new guidelines for snakebite first aid, and a new test for snakebites that would identify which snake had envenomated the victim. Other major achievements of CSL include:
Nicotinate riboside kinase (EC 2.7.1.173, ribosylnicotinic acid kinase, nicotinic acid riboside kinase, NRK1) is an enzyme that in humans is encoded by the genes NMRK1 and NMRK2. Its systematic name ATP:beta-D-ribosylnicotinate 5-phosphotransferase, and it catalyses the following chemical reaction:
vector Any DNA molecule used as a vehicle to artificially transport foreign genetic material into another cell, where it can be replicated and/or expressed. Vectors are typically engineered recombinant DNA sequences consisting of an insert (often a transgene) and a longer "backbone" sequence containing an origin of replication, a multiple cloning site, and a selectable marker. Vectors are widely used in molecular biology laboratories to isolate, clone, or express the insert in the target cell.
In June 2019, Pritzker signed into law Senate Bill 25, or the Reproductive Health Act. The act repealed the Illinois Abortion Law of 1975, which penalized doctors for performing abortions considered "unnecessary", and the "Partial-Birth Abortion Ban Act". The new bill ensured the "fundamental right to make autonomous decisions about one's own reproductive health", specifically the right to choose whether to carry a pregnancy to term or to terminate it, and denies a zygote, an embryo, or a fetus "independent rights under the law" of the State of Illinois. Pritzker encouraged other states that had passed restrictions on abortion to reconsider their positions and said that women from other states could access medical services in Illinois. After Dobbs v. Jackson overturned Roe v. Wade in 2022, Illinois became an abortion-access state for people in the South and Midwest whose states ban abortion, with 30% of abortions being for out-of-state residents. Abortions in Illinois increased by over 45% in the year after Roe was overturned, primarily due to patients' traveling from states with abortion bans. In 2024, Pritzker signed the Birth Equity Act, which required Illinois-based health insurance providers to cover abortion care without copayments or deductibles. On June 24, 2026, Pritzker signed the Reproductive Health Records Privacy Act, a law that protects those seeking abortions in Illinois by shielding digital medical records from out-of-state entities, effective July 1, 2027.
Sources: en.wikipedia.org
=== Reorganization === In January 2006, the division began reorganizing from a division based organization to a brigade combat team-based organization. Activated elements include a 4th Brigade Combat Team, 82nd Airborne Division (1–508th INF, 2–508th INF, 4–73rd Cav (RSTA), 2–321st FA, 782nd BSB, and STB, 4th BCT) and the inactivation of the Division Artillery, 82nd Signal Battalion, 307th Engineer Battalion, and 313th Military Intelligence Battalion. The 82nd Division Support Command (DISCOM) was redesignated as the 82nd Sustainment Brigade. A pathfinder unit was reactivated within the 82nd when the Long Range Surveillance Detachment of the inactivating 313th Military Intelligence Battalion was transferred to the 2d Battalion, 82nd Aviation Regiment and converted to a pathfinder role as the battalion's Company F.
=== Other types of conjugated proteins === Apart from the mentioned types of conjugated proteins, there are several other types of conjugated proteins that are categorized by their prosthetic groups. Nucleoproteins are proteins associated with nucleic acids, which are important in processes such as DNA replication and gene expression. phosphoproteins are another protein that have phosphate groups. Phosphoproteins can help regulate protein activity through phosphorylation. These additional categories further demonstrate the wide scope of functions performed by conjugated proteins in biological systems. Chemical synthesized polysaccharide–protein conjugates been used for food industry, vaccines, and drug delivery systems. They are promising alternatives to PEG–protein drugs, in which non-biodegradable high molecular weight PEG causes health concerns.
However, the military tide began to turn swiftly in favor of Franz Joseph and the Austrian whitecoats. Almost immediately, Charles Albert was decisively beaten by Radetzky at Novara and forced to sue for peace, as well as to renounce his throne.
=== Regulation of expression === EPCIP is expressed during blastocyst, fetus, and adult states of human development. It is overexpressed during some tumor states, including pancreatic, gastrointestinal, germ cell, and glioma tumors.
== In medicine == In medicine, immunophilins act as receptors for immunosuppressive drugs such as sirolimus (rapamycin), cyclosporin (such as CsA) and tacrolimus (FK506), which inhibit the prolyl isomerase activity of the immunophilins. The drug-immunophilin complexes (CsA-CyP and FK506-FKBP) bind to calcineurin, which inhibits the phosphatase activity of calcineurin and engenders the immunosuppressive effects. CsA and FK506 thus affect the calcium-dependent step of T cell response which prevents release of interleukin-2. Immunophilins also form protein complex with ryanodine and inositol triphosphate (IP3) which impacts the release of calcium. FK506 binds with high affinity to other smaller proteins, such as FKBP-12. FKBP-12 and cyclophilins both share common peptide-prolyl isomerase activity. While the majority of the Peptide bonds within proteins exist in trans (planar) conformation because of the partial double-bond nature of the peptide bond, a small fraction occurs in cis. Unlike regular peptide bonds, the X-Pro peptide bond does not adopt the intended trans conformation spontaneously, thus, cis-trans isomerization can be the rate-limiting (slowest) step in the process of protein folding. Immunophilins, with their prolyl isomerase activity, thus function as protein-folding chaperones.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.